AmJan

Amgen is a global biotechnology leader dedicated to transforming new ideas into medicines for patients with serious illnesses. Founded in 1980, the company has grown into one of the world's largest independent biotech firms, focusing on oncology, inflammation, cardiovascular disease, and bone health. Amgen's innovative approach leverages advanced human genetics and its proprietary BiTE (Bispecific T-cell Engager) platform to develop first-in-class cancer immunotherapies. The company maintains a robust commercial portfolio, including blockbuster drugs like Enbrel, Prolia, and Repatha, while advancing a deep pipeline of biologics and small molecules. Amgen's 2023 acquisition of Horizon Therapeutics further expanded its presence in rare disease treatments, solidifying its position as a diversified biopharmaceutical powerhouse.